Showing results (71-80 of 773) with videos related to
Sort By:
Pageof 78
JAMA Network Open|April 19, 2022
Use of Extrapolation in New Drug Approvals by the US Food and Drug AdministrationDaniel Feldman, Jerry Avorn, Aaron S KesselheimAmerican Heart Journal|April 29, 2008
The economic consequences of non-evidence-based clopidogrel useNiteesh K Choudhry, Raisa Levin, Jerry AvornArchives of Internal Medicine|January 25, 2006
Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effectsWinfried Rief, Jerry Avorn, Arthur J BarskyPharmacoepidemiology and Drug Safety|February 18, 2010
Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databasesJeremy A Rassen, Jerry Avorn, Sebastian SchneeweissAmerican Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 25, 2002
Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgeryWolfgang C Winkelmayer, Raisa Levin, Jerry AvornPain Physician|February 23, 2017
Educational Outreach to Opioid Prescribers: The Case for Academic DetailingMargot Trotter Davis, Brian Bateman, Jerry AvornThe New England Journal of Medicine|March 28, 2008
Drug-review deadlines and safety problemsDaniel Carpenter, Evan James Zucker, Jerry AvornKidney International|April 5, 2003
The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney diseaseWolfgang C Winkelmayer, Raisa Levin, Jerry AvornJAMA Internal Medicine|August 25, 2015
Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014Jing Luo, Jerry Avorn, Aaron S KesselheimPlos One|February 18, 2014
Clinicians' contributions to the development of coronary artery stents: a qualitative study of transformative device innovationAaron S Kesselheim, Shuai Xu, Jerry AvornPageof 78